Bone marrow niche cells and method for producing same
By differentiating pluripotent stem cells with GSK3β inhibitors and fibroblast growth factors, MSCs are produced that support hematopoietic cells and can replace invasive bone marrow-derived MSCs, addressing the scarcity and collection challenges of traditional methods.
Patent Information
- Application Number
- PCT/JP2024/019183
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
The challenge lies in efficiently producing mesenchymal stem cells (MSCs) for bone marrow niche cells, as their isolation from rare human specimens is invasive and yields insufficient quantities, necessitating an alternative method for obtaining these cells that support hematopoietic stem/progenitor cells.
A method involving the differentiation of pluripotent stem cells using a GSK3β inhibitor and fibroblast growth factors to produce CD271 and SSEA-4 positive mesenchymal stem cells, which exhibit similar morphology and functionality to bone marrow-derived MSCs, thereby providing a non-invasive means of obtaining these cells.
This method allows for the successful production of MSCs that can support hematopoietic stem/progenitor cells and can be used for differentiation into various mesenchymal cell types, offering a viable alternative to invasive specimen collection and ensuring a sufficient cell supply.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure 00000026_0000 
Figure 00000026_0001
Abstract
Description
Bone marrow niche cells and method for producing same
[0001] The present invention relates to bone marrow niche cells and a method for producing the same, etc. More specifically, the present invention relates to bone marrow niche cells derived from pluripotent stem cells, a method for producing the cells, and uses of the cells, etc.
[0002] Mesenchymal stem cells (MSCs) are found at low frequencies in mesenchymal tissues and are thought to exist in tissues and organs throughout the body, although their frequency may vary. Bone marrow mesenchymal stem cells are found among bone marrow stromal cells and are a type of cell that supports hematopoietic cells. In addition to bone marrow, mesenchymal stem cells have been isolated from various tissues, including adipose tissue, placenta, umbilical cord tissue, and dental pulp.
[0003] The present inventors have previously isolated mesenchymal stem cells capable of supporting human hematopoietic stem / progenitor cells from human bone marrow samples using the Lineage - CD271 + SSEA-4 + reported that BM-DP MSCs can be isolated from a BM fraction (Non-Patent Document 1, Patent Document 1). The CD271-positive, SSEA-4-positive mesenchymal stem cells (DP MSCs) isolated in this manner exhibited a higher ability to support human hematopoietic stem / progenitor cells in culture than mesenchymal stem cells established from other fractions. Based on this, these BM-DP MSCs were considered to be candidates for niche cells within the human bone marrow. Furthermore, similar isolation of DP MSCs from human bone samples was also successfully achieved (Patent Document 1).
[0004] Patent Publication No. 2015-39307
[0005] Matsuoka Y et al., Stem Cells. 33(5):1554-65, 2015
[0006] However, the above-mentioned mesenchymal stem cells need to be isolated from rare human specimens, sample collection is invasive, and it has been difficult to obtain sufficient quantities of mesenchymal stem cells. Therefore, an objective of the present invention is to provide a method for producing mesenchymal stem cells from pluripotent stem cells, and mesenchymal stem cells produced by said method.
[0007] The present inventors were inducing differentiation of pluripotent stem cells into skeletal muscle cells for research using skeletal muscle cells. During this research, they accidentally discovered that if a GSK3β inhibitor, which is usually removed from the culture medium after 5–6 days of culture, was continued, a small number of fibroblast-like cells with a morphology distinct from skeletal myoblasts were generated. To analyze these fibroblast-like cells, they first attempted to expand them. As a result, they were successfully expanded by adding fibroblast growth factor to the culture medium. Analysis of the fibroblast-like cells thus obtained revealed that their morphology and cell surface antigen characteristics were similar to those of bone marrow-derived CD271- and SSEA-4-copositive mesenchymal stem cells (BM-DP MSCs), and their ability to maintain hematopoietic stem / progenitor cells in culture was equivalent to that of BM-DP MSCs. Therefore, the present inventors concluded that the fibroblast-like cells were induced DP MSCs (iDP MSCs) derived from pluripotent stem cells. The present inventors have conducted further research based on these findings and have completed the present invention.
[0008] That is, the present invention is as follows. [1-1] A method for producing mesenchymal stem cells from pluripotent stem cells, comprising: (1) culturing the pluripotent stem cells in a medium containing a GSK-3β inhibitor to obtain fibroblast-like cells; and (2) culturing the fibroblast-like cells obtained in step (1) in a medium containing a fibroblast growth factor and a GSK-3β inhibitor to obtain mesenchymal stem cells. [1-2] The method according to [1-1], wherein at least one of the GSK-3β inhibitors in step (1) is CHIR99021. [1-3] The method according to [1-1] or [1-2], wherein the medium in step (1) and / or (2) contains at least one selected from the group consisting of insulin, transferrin, sodium selenite, and ethanolamine. [2-1] The method according to any one of [1-1] to [1-3], comprising: (3) expanding the cells obtained in step (2). [2-2] The method according to [2-1], wherein step (3) is culturing cells in a medium containing serum. [3-1] The method according to any one of [1-1] to [2-2], wherein at least one of the fibroblast growth factors in step (2) is bFGF. [3-2] The method according to any one of [1-1] to [3-1], wherein at least one of the GSK3β inhibitors in step (2) is CHIR99021. [4] The method according to any one of [1-1] to [3-2], wherein the mesenchymal stem cells are positive for CD271 and SSEA-4. [5-1] The method according to any one of [1-1] to [4], wherein the pluripotent stem cells are induced pluripotent stem cells. [5-2] The method according to any one of [1-1] to [5-1], wherein the pluripotent stem cells are derived from humans. [6] Mesenchymal stem cells obtained by the method according to any one of [1-1] to [5-2]. [7] A method for maintaining hematopoietic stem / progenitor cells, comprising a step of co-culturing hematopoietic stem / progenitor cells with the cells described in [6]. [8] A method for producing mesenchymal cells, comprising a step of inducing differentiation of the cells described in [6]. [9] A cell transplantation therapeutic agent, comprising the cells described in [6] or cells obtained by the method described in [8].
[10] The agent described in [9], comprising hematopoietic stem / progenitor cells.[11-1] A method for treating or preventing tissue damage or disease, comprising administering to or transplanting into a subject an effective amount of the cells according to [6] or cells obtained by the method according to [8]. [11-2] The method according to [11-1], comprising administering to or transplanting into a subject an effective amount of hematopoietic stem / progenitor cells.
[12] The cells according to [6] or cells obtained by the method according to [8] for use in treating or preventing tissue damage or disease.
[13] Use of the cells according to [6] or cells obtained by the method according to [8] in the manufacture of a medicament for treating or preventing tissue damage or disease.
[0009] The present invention makes it possible to produce mesenchymal stem cells (niche cells) by inducing differentiation from pluripotent stem cells without using precious bone marrow samples, which require invasive collection. The mesenchymal stem cells have the ability to support hematopoietic stem / progenitor cells and can also be used as starting cells for inducing differentiation into mesenchymal cells.
[0010] An overview of the method for inducing pluripotent stem cells into iDP MSCs is shown. A comparison of the morphology of BM-DP MSCs and iDP MSCs is shown. Scale bar: 200 μm. A comparison of the expression of surface antigens (positive and negative markers) between BM-DP MSCs and iDP MSCs is shown. Analysis was performed by flow cytometry using antibodies against each surface antigen. A comparison of the ability of BM-DP MSCs and iDP MSCs to support human hematopoietic stem / progenitor cells is shown. A FACS plot (top) of cells recovered after one week of co-culture of human umbilical cord blood-derived hematopoietic stem / progenitor cells with BM-DP MSCs and each iDP MSC, and the expression of hematopoietic stem / progenitor cells (CD34 + Graph of the percentage of cells (bottom).
[0011] 1. Method for Producing Bone Marrow Niche Cells The present invention provides a method for producing mesenchymal stem cells (MSCs) (also referred to as "bone marrow niche cells") from pluripotent stem cells. Specifically, this method comprises the steps of: (1) culturing pluripotent stem cells in a medium containing a GSK3β inhibitor to obtain fibroblast-like cells; and (2) culturing the fibroblast-like cells obtained in step (1) in a medium containing a fibroblast growth factor and a GSK3β inhibitor to obtain mesenchymal stem cells (hereinafter, this may be referred to as the "method for producing MSCs of the present invention").
[0012] The pluripotent stem cells used in the present invention may be any undifferentiated cells that possess both the "self-renewal ability" (ability to proliferate while maintaining an undifferentiated state) and the "pluripotency" (ability to differentiate into all three primary germ layers). Examples of such pluripotent stem cells include induced pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), embryonic stem cells derived from cloned embryos obtained by nuclear transfer (nuclear transfer embryonic stem cells (ntES cells)), multipotent germline stem cells (mGS cells), and embryonic germ stem cells (EG cells). Preferably, these are iPS cells (more preferably, human iPS cells). When the pluripotent stem cells are ES cells or any cells derived from human embryos, they may be produced by or without the destruction of embryos. However, from an ethical standpoint, they are preferably produced without the destruction of embryos.
[0013] iPS cells are artificial stem cells derived from somatic cells that can be produced by introducing specific reprogramming factors into somatic cells in the form of DNA or protein. They have properties similar to those of ES cells, such as pluripotency and the ability to proliferate through self-renewal (Takahashi K. and Yamanaka S. (2006) Cell, 126:663-676; Takahashi K. et al. (2007), Cell, 131:861-872; Yu J. et al. (2007), Science, 318:1917-1920; Nakagawa M. et al., Nat. Biotechnol.26:101-106 (2008); WO 2007 / 069666). When iPS cells are used, the iPS cells may be produced from somatic cells by a method known per se, or iPS cells that have already been established and stored may be used. The reprogramming factors may be composed of genes that are specifically expressed in ES cells, their gene products, or non-coding RNAs, or genes that play an important role in maintaining the undifferentiated state of ES cells, their gene products, or non-coding RNAs, or low-molecular-weight compounds. Examples of genes contained in the reprogramming factors include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3, and Glis1. These reprogramming factors may be used alone or in combination. Combinations of reprogramming factors include WO 2007 / 069666, WO 2008 / 118820, WO 2009 / 007852, WO 2009 / 032194, WO 2009 / 058413, WO 2009 / 057831, WO 2009 / 075119, WO 2009 / 079007, WO 2009 / 091659, WO 2009 / 101084, WO 2009 / 101407, WO 2009 / 102983, WO 2009 / 114949, WO 2009 / 117439, WO 2009 / 126250, WO 2009 / 126251, WO 2009 / 126655, WO 2009 / 157593, WO 2010 / 009015, WO 2010 / 033906, WO 2010 / 033920, WO 2010 / 042800, WO 2010 / 050626, WO 2010 / 056831, WO 2010 / 068955, WO 2010 / 098419, WO 2010 / 102267, WO 2010 / 111409, WO 2010 / 111422, WO 2010 / 115050, WO 2010 / 124290, WO 2010 / 147395, WO 2010 / 147612, Huangfu D, et al. (2008), Nat.Combinations described in Biotechnol., 26:795-797, Shi Y, et al. (2008), Cell Stem Cell, 2:525-528, Eminli S, et al. (2008), Stem Cells. 26:2467-2474, Huangfu D, et al. (2008), Nat Biotechnol. 26:1269-1275, Shi Y, et al. (2008), Cell Stem Cell, 3, 568-574, Zhao Y, et al. (2008), Cell Stem Cell, 3:475-479, Marson A, (2008), Cell Stem Cell, 3, 132-135, Feng B, et al. (2009), Nat Cell Biol. 11:197-203, R.L. Judson et al., (2009), Nat. Biotech., 27:459-461, Lyssiotis CA, et al. (2009), Proc Natl Acad Sci U S A. 106:8912-8917, Kim JB, et al. (2009), Nature. 461:649-643, Ichida JK, et al. (2009), Cell Stem Cell. 5:491-503, Heng JC, et al. (2010), Cell Stem Cell. 6:167-74, Han J, et al. (2010), Nature. 463:1096-100, Mali P, et al. (2010), Stem Cells. 28:713-720, Maekawa M, et al. (2011), Nature. 474:225-9 are exemplified.
[0014] ES cells are stem cells that are established from the inner cell mass of early mammalian embryos (e.g., blastocysts) such as humans and mice, and have the ability to proliferate through pluripotency and self-renewal. ES cells were discovered in mice in 1981 (MJ Evans and MH Kaufman (1981), Nature 292:154-156), and subsequently, ES cell lines were established in humans, monkeys, and other primates (JA Thomson et al. (1998), Science 282:1145-1147; JA Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92:7844-7848; JA Thomson et al. (1996), Biol. Reprod., 55:254-259; JA Thomson and VS Marshall (1998), Curr. Top. Dev. Biol., 38:133-165). ES cells can be established by extracting the inner cell mass from the blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder. Methods for establishing and maintaining human and monkey ES cells are described, for example, in US Pat. No. 5,843,780; Thomson JA, et al. (1995), Proc. Natl. Acad. Sci. USA 92:7844-7848; Thomson JA, et al. (1998), Science. 282:1145-1147; Suemori H. et al. (2006), Biochem. Biophys. Res. Commun., 345:926-932; Ueno M. et al. (2006), Proc. Natl. Acad. Sci. USA 103:9554-9559; Suemori H. et al. (2001), Dev. Dyn., 222:273-279; Kawasaki H. et al. (2002), Proc. Natl. Acad. Sci. USA, 99:1580-1585; Klimanskaya I. et al. (2006), Nature. 444:481-485, etc.Alternatively, ES cells can be established using only a single blastomere from an embryo at the cleavage stage prior to the blastocyst stage (Chung Y. et al. (2008), Cell Stem Cell 2: 113-117), or from a developmentally arrested embryo (Zhang X. et al. (2006), Stem Cells 24: 2669-2676).
[0015] ntES cells are ES cells derived from cloned embryos by nuclear transfer technology and have almost the same properties as ES cells derived from fertilized eggs (Wakayama T. et al. (2001), Science, 292:740-743; S. Wakayama et al. (2005), Biol. Reprod., 72:932-936; Byrne J. et al. (2007), Nature, 450:497-502). Specifically, ntES (nuclear transfer ES) cells are established from the inner cell mass of blastocysts derived from cloned embryos obtained by replacing the nucleus of an unfertilized egg with that of a somatic cell. To generate ntES cells, nuclear transfer technology (Cibelli JB et al. (1998), Nature Biotechnol., 16:642-646) is combined with ES cell generation technology (see above) (Wakayama Sayaka et al. (2008), Experimental Medicine, Vol. 26, No. 5 (Special Issue), pp. 47-52). In nuclear transfer, the nucleus of a somatic cell is injected into an enucleated unfertilized mammalian egg, and the egg is then cultured for several hours to reprogram the embryo.
[0016] mGS cells are pluripotent stem cells derived from the testis and are the source of spermatogenesis. Similar to ES cells, these cells can be induced to differentiate into various cell lineages, e.g., when transplanted into mouse blastocysts, chimeric mice can be generated (Kanatsu-Shinohara M. et al. (2003) Biol. Reprod., 69:612-616; Shinohara K. et al. (2004) Cell, 119:1001-1012). They are capable of self-renewal in culture medium containing glial cell line-derived neurotrophic factor (GDNF). Furthermore, germline stem cells can be obtained by repeated passage under culture conditions similar to those for ES cells (Takebayashi M. et al. (2008) Experimental Medicine, Vol. 26, No. 5 (Special Issue), pp. 41-46, Yodosha, Tokyo, Japan).
[0017] EG cells are derived from embryonic primordial germ cells (PGCs) and have pluripotency similar to that of ES cells. They can be established by culturing PGCs in the presence of LIF, bFGF, stem cell factor, and other substances (Matsui Y. et al. (1992), Cell, 70:841-847; JL Resnick et al. (1992), Nature, 359:550-551).
[0018] The species from which the pluripotent stem cells are derived is not particularly limited, and may be cells from, for example, rodents such as rats, mice, hamsters, and guinea pigs, lagomorphs such as rabbits, ungulates such as pigs, cows, goats, and sheep, carnivores such as dogs and cats, and primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees. The preferred species is human.
[0019] In the present invention, a cell may be a single cell, but is typically a cell population consisting of multiple cells. Thus, in this specification, unless otherwise specified, the term "cell" includes a "cell population." A cell population may be composed of one type of cell, or two or more types of cells.
[0020] The method for producing MSCs of the present invention may also include a step (3) of expanding the mesenchymal stem cells obtained in step (2). As used herein, "expansion" refers to culturing a desired cell population with the goal of expanding the cell population and increasing the cell number. The increase in cell number can be achieved by the increase in cell number due to cell proliferation exceeding the decrease in cell number due to cell death; it is not necessary for all cells in the cell population to proliferate. The increase in cell number can be 1.1-fold, 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 300-fold, 500-fold, 1000-fold, 3000-fold, 5000-fold, 10000-fold, or more compared to before the start of expansion.
[0021] Step (3) of the method for producing MSCs of the present invention is not particularly limited as long as it allows the proliferation of mesenchymal stem cells, and can be carried out, for example, by culturing them in a mesenchymal stem cell maintenance medium (e.g., a basal medium (e.g., αMEM medium) containing serum (e.g., 10% FBS)).
[0022] Furthermore, the method for producing MSCs of the present invention may include a step of pre-culturing pluripotent stem cells to adjust colony size prior to step (1). Such a step may involve, for example, seeding an appropriate number of colonies (e.g., 5 or 6 colonies per well) into a culture vessel and culturing the cells until the median colony size reaches 40 to 60 cells / colony (particularly, 50 cells / colony). In this culturing step, the cells are typically cultured in a pluripotent stem cell maintenance medium (e.g., a basal medium containing bFGF (e.g., NutriStem medium)).
[0023] The method for producing MSCs of the present invention may include a step of isolating or purifying mesenchymal stem cells after the above step (2) or (3). By performing such a step, the proportion of mesenchymal stem cells in the cell population can be increased. The isolation or purification method can be performed by a method known per se. Examples include labeling with an antibody against an indicator molecule (e.g., a surface antigen marker such as CD271 or SSEA-4) and purifying using flow cytometry or mass cytometry, magnetic cell separation, or an affinity column on which a desired antigen is immobilized.
[0024] Examples of GSK3β inhibitors used in the method for producing MSCs of the present invention include CHIR98014 (2-[[2-[(5-nitro-6-aminopyridin-2-yl)amino]ethyl]amino]-4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidine), CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]nicotinonitrile), CP21R7 (3-(3-aminopyridin-2-yl)pyrimidinyl)amino]ethyl]amino]nicotinonitrile), and CP21R8 (3-(3-aminopyridin-2-yl)pyrimidinyl)amino]ethyl]amino). (1-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione), LY2090314 (3-[9-Fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1h-pyrrole-2,5-dione), TDZD-8 (4-benzyl-2-methyl-1,2,4- Thiadiazolidine-3,5-dione), SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), TWS-119 (3-[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenol), Kenpaullone, 1-Azakenpaullone, SB415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4-( Examples of suitable amines include (2-nitrophenyl)-1H-pyrrole-2,5-dione), AR-AO144-18 (1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea), CT99021, CT20026, BIO ((2'Z,3'E)-6-bromoindirubin-3'-oxime), BIO-acetoxime, pyridocarbazole-cyclopentadienyl ruthenium complex, OTDZT, alpha-4-dibromoacetophenone, and lithium. Among these, CHIR99021 is preferred. These amines may be used alone or in combination of two or more.In addition, antisense oligonucleotides and siRNAs against GSK3β mRNA, antibodies that bind to GSK3β, dominant-negative GSK3β mutants, etc. can also be used as GSK3β inhibitors, and these are commercially available or can be synthesized according to known methods.
[0025] In the method for producing MSCs of the present invention, the concentration of the GSK3β inhibitor in the medium is adjusted appropriately depending on the type of GSK3β inhibitor added, but when CHIR99021 is used, for example, the concentration is typically 0.1 to 1 μM, preferably 0.5 to 1 μM, and more preferably 1 μM. For example, the concentration is 0.01 to 20 μM, preferably 0.1 to 15 μM, and more preferably 0.5 to 10 μM (particularly 3.5 μM).
[0026] Commercially available fibroblast growth factors (FGFs) can be used in the MSC production method of the present invention. Twenty-two types of FGF are known in humans, and any that function as a cell growth factor can be used; however, bFGF (also known as FGF-2) is preferred. FGFs may be used alone or in combination of two or more. The concentration of FGF in the medium can be appropriately selected by those skilled in the art depending on the FGF used; for example, when bFGF is used, the concentration is typically 0.1 to 200 ng / ml, preferably 1 to 100 ng / ml, and more preferably 10 to 50 ng / ml (particularly 20 ng / ml).
[0027] The culture period in step (1) of the method for producing MSCs of the present invention is not particularly limited as long as it is a period during which fibroblast-like cells appear, but is typically 3 to 8 days, preferably 4 to 7 days, and more preferably 5 to 6 days.
[0028] The culture period in step (2) of the MSC production method of the present invention is not particularly limited as long as it is a period during which mesenchymal stem cells appear, but is typically 3 to 8 days, preferably 4 to 7 days, and more preferably 5 to 6 days.
[0029] The culture period in step (3) of the MSC production method of the present invention is not particularly limited, as mesenchymal stem cells are maintained and proliferated in step (3), but is typically 5 to 50 days, preferably 10 to 40 days, and more preferably 15 to 30 days.
[0030] Examples of basal media used in the method for producing MSCs of the present invention include, but are not limited to, Neurobasal medium, Neural Progenitor Basal medium, NS-A medium, BME medium, BGJb medium, CMRL 1066 medium, Minimum Essential Medium (MEM), Eagle MEM medium, αMEM medium, Dulbecco's Modified Eagle Medium (DMEM), Glasgow MEM medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, DMEM / F12 medium, Ham's medium, RPMI 1640 medium, Fischer's medium, and mixed media thereof.
[0031] The medium may be serum-containing or serum-free. In one embodiment, a serum-free medium is used in steps (1) and (2) of the method for producing MSCs of the present invention. In another embodiment, a serum-containing medium is used in step (3) of the method for producing MSCs of the present invention. Serum-free medium (SFM) refers to a medium that does not contain any untreated or unpurified serum. When serum (e.g., fetal bovine serum (FBS), human serum, etc.) is used, its concentration in the medium may be 5-30%, preferably 10-20%. SFM may or may not contain any serum substitute. Examples of serum substitutes include substances that appropriately contain albumin (e.g., lipid-rich albumin, albumin substitutes such as recombinant albumin, plant starch, dextran, and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, sodium selenite, 2-mercaptoethanol, ethanolamine, 3'-thioglycerol, or equivalents thereof. Such serum replacements can be prepared, for example, by the method described in WO 98 / 30679. Alternatively, for convenience, commercially available products can be used. Examples of such commercially available products include Knockout™ Serum Replacement (KSR), Chemically-defined Lipid concentrated, Glutamax (Invitrogen), and ITS supplements (e.g., ITS-G, ITS-A, and ITS-X, all manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.).
[0032] The medium may contain other additives known per se. These additives are not particularly limited, but examples include growth factors (e.g., insulin, etc.), polyamines (e.g., putrescine, etc.), minerals (e.g., sodium selenate, etc.), sugars (e.g., glucose, etc.), organic acids (e.g., pyruvic acid, lactic acid, etc.), amino acids (e.g., non-essential amino acids (NEAA), L-glutamine, etc.), reducing agents (e.g., 2-mercaptoethanol, etc.), vitamins (e.g., ascorbic acid, d-biotin, etc.), steroids (e.g., [beta]-estradiol, progesterone, etc.), antibiotics (e.g., streptomycin, penicillin, gentamicin, etc.), buffers (e.g., HEPES, etc.), and nutritional additives (e.g., B27 supplement, N2 supplement, StemPro-Nutrient Supplement, etc.). Each additive is preferably contained within a concentration range known per se.
[0033] In one embodiment, the medium used in step (1) and / or (2) of the method for producing MSCs of the present invention contains at least one (preferably all) selected from the group consisting of insulin, transferrin, sodium selenite, and ethanolamine. The concentration of insulin in the medium is typically 0.1 to 100 μg / mL, preferably 1 to 50 μg / mL, more preferably 3 to 20 μg / mL (particularly 10 μg / mL). The concentration of transferrin in the medium is typically 0.1 to 100 μg / mL, preferably 1 to 50 μg / mL, more preferably 2 to 10 μg / mL (particularly 5.5 μg / mL). The concentration of sodium selenite in the medium is typically 0.1 to 100 μg / L, preferably 1 to 50 μg / L, more preferably 2 to 10 μg / L (particularly 6.7 μg / L). The concentration of ethanolamine in the medium is typically 0.1 to 100 μg / mL, preferably 0.5 to 50 μg / mL, more preferably 1 to 5 μg / mL (particularly 2 μg / mL).
[0034] The culture in each step of the MSC production method of the present invention may be either adherent culture or suspension culture. Adherent culture may be performed using a culture vessel coated with an extracellular matrix component, or co-culture with feeder cells. Examples of feeder cells include, but are not limited to, fibroblasts (mouse embryonic fibroblasts (MEF) and mouse fibroblasts (STO)). Feeder cells are preferably inactivated by known methods, such as irradiation (e.g., gamma rays) or treatment with anticancer drugs (e.g., mitomycin C). Examples of extracellular matrix components include Matrigel (Niwa A, et al., PLoS One. 6(7):e22261, 2011), fibrous proteins such as gelatin, collagen, and elastin, glycosaminoglycans and proteoglycans such as hyaluronic acid and chondroitin sulfate, and cell adhesive proteins such as fibronectin, vitronectin, and laminin. In one embodiment, in steps (1) and (2) of the method for producing MSCs of the present invention, a culture vessel coated with Matrigel is used.
[0035] The culture vessel used for culture is not particularly limited, but examples include flasks, tissue culture flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, multi-plates, multi-well plates, microslides, chamber slides, petri dishes, tubes, trays, culture bags, roller bottles, etc.
[0036] The culture temperature is not particularly limited, but is about 30 to about 40°C, preferably about 37°C, and the culture is carried out in the presence of CO2-containing air, with the CO2 concentration preferably being about 2 to 5%.
[0037] As used herein, "mesenchymal stem cells (MSCs)" refer to stem cells that have a fibroblast-like morphology and are positive for the surface antigen markers CD73, CD90, and CD105, and these MSCs typically have the ability to differentiate into one or more types of mesenchymal cells (e.g., osteoblasts, chondrocytes, adipocytes, etc.). In another aspect of the present invention, MSCs obtained by the MSC production method of the present invention (hereinafter, sometimes referred to as "MSCs of the present invention") are also provided. The MSCs of the present invention typically have the following characteristics (A) and (B) in addition to the characteristics of the MSCs described above. (A) They are derived from pluripotent stem cells. (B) They are positive for the surface antigen markers CD271 and SSEA-4.
[0038] Furthermore, the MSCs of the present invention may further have at least one (preferably all) of the following characteristics (C) to (E): (C) They have the ability to support hematopoietic stem / progenitor cells; (D) They are positive for at least one (preferably all) of the surface antigen markers selected from CD29, CD44, and HLA-ABC; and (E) They are negative for at least one (preferably all) of the surface antigen markers selected from CD31, CD34, CD41, CD45, and HLA-DR.
[0039] As used herein, the phrase "a surface antigen marker is positive" (or "a surface antigen marker is expressed") includes the meaning of "the production of a protein encoded by mRNA." Therefore, when the production of a protein encoded by mRNA is detected at a level above background, at least by the method (cell sorting) described in the Examples below, it can be said that the surface antigen marker is expressed. On the other hand, when the production of the protein is not detected by the same method (cell sorting) (i.e., below the detection limit) or is at background levels, it can be said that the surface antigen marker is negative.
[0040] As used herein, "having the ability to support hematopoietic stem / progenitor cells" means that when cocultured with hematopoietic stem / progenitor cells, differentiation of hematopoietic stem / progenitor cells into other cells is prevented (in other words, hematopoietic stem / progenitor cells are maintained). When cocultured with MSCs and hematopoietic stem / progenitor cells results in a higher proportion of hematopoietic stem / progenitor cells in the cell population compared to when hematopoietic stem / progenitor cells are cultured for the same period in the absence of the MSCs, the MSCs can be evaluated as having the ability to support hematopoietic stem / progenitor cells. Furthermore, as used herein, "hematopoietic stem / progenitor cells (HSPCs)" is a general term encompassing hematopoietic stem cells and hematopoietic progenitor cells. They are CD133- and CD45-positive and have the ability to differentiate into other cells of the hematopoietic lineage. Hematopoietic stem / progenitor cells are typically CD34-positive, but may also be CD34-negative cells that can be found in umbilical cord blood. Examples of the hematopoietic stem / progenitor cells include hematopoietic stem cells, hematopoietic progenitor cells, myeloid progenitor cells, megakaryocyte progenitor cells, and lymphoid progenitor cells.
[0041] As described above, in one embodiment, the MSCs of the present invention have the ability to support hematopoietic stem / progenitor cells. Therefore, in another embodiment, the present invention provides a method for maintaining hematopoietic stem / progenitor cells, comprising the step of co-culturing hematopoietic stem / progenitor cells with the MSCs of the present invention. The hematopoietic stem / progenitor cells used in the present invention may be cells isolated from a living body (e.g., bone marrow, umbilical cord, peripheral blood, etc.) by known methods, commercially available cells, or cells induced to differentiate from pluripotent stem cells (e.g., induced pluripotent stem cells derived from the individual to be transplanted).
[0042] 2. Differentiation Induction Method and Mesenchymal Cells Obtained by the Method The MSCs of the present invention can differentiate into various cells. Therefore, in another aspect, a method for producing mesenchymal cells (hereinafter sometimes referred to as the "method for producing mesenchymal cells of the present invention"), which includes a step of inducing differentiation of the MSCs of the present invention, and mesenchymal cells obtained by the method (hereinafter sometimes referred to as the "mesenchymal cells of the present invention") are provided. Examples of such mesenchymal cells include mesenchymal cells other than mesenchymal stem cells, such as bone cells, chondrocytes, adipocytes, cardiac muscle cells, and skeletal muscle cells, as well as their precursor cells (e.g., osteoprogenitor cells, osteoblasts, chondroprogenitor cells, chondroblasts, adipocytes, cardiac muscle stem cells, skeletal muscle stem cells, myoblasts, etc.).
[0043] The method for producing mesenchymal cells of the present invention is typically carried out by culturing the MSCs of the present invention in a mesenchymal cell differentiation-inducing medium. For example, the osteocyte differentiation-inducing medium may be a basal medium (e.g., αMEM) containing 10% FBS, 0.1 μM dexamethasone, 50 μg / ml ascorbic acid, and 10 mM β-glycerophosphate, or a commercially available xeno-free osteocyte differentiation-inducing medium (e.g., MSCgo). TM Rapid Osteogenic Differentiation Medium (Biological Industries) and the like. Specific examples of the differentiation method into bone cells include, for example, placing 4 × 10 mesenchymal stem cells in a 12-well plate coated with gelatin. 4 For example, individual cells are seeded on the cells and cultured for 30 days in the osteocyte differentiation-inducing medium. Differentiation into osteocytes may be confirmed by detecting mineralized nodules using alizanin red staining.
[0044] The chondrocyte differentiation induction medium may be a basal medium (e.g., DMEM / F12) containing 1% (v / v) ITS+premix, 0.17 mM AA2P, 0.35 mM proline, 0.1 mM dexamethasone, 0.15% (v / v) glucose, 1 mM sodium pyruvate, 2 mM GlutaMAX, 40 ng / ml PDGF-BB, 100 ng / mL TGF-β3, 10 ng / ml BMP4, and 1% (v / v) FBS, or a commercially available xeno-free chondrocyte differentiation induction medium (e.g., MSCgo TM Chondrogenic XF (Biological Industries) and the like. Specific methods for differentiation into chondrocytes include spotting 5 μl of mesenchymal stem cell suspension onto a fibronectin-coated plate, culturing for 1 hour, adding 1 ml of the above-mentioned differentiation-inducing medium after 1 hour, and culturing for 14 days. Chondrocyte differentiation may be confirmed by Alcian blue staining.
[0045] Adipocyte differentiation induction media include basal medium containing 60 μM indomethacin, 0.5 mM IBMX, and 0.5 μM hydrocortisone, and commercially available xeno-free adipocyte differentiation induction media (e.g., hMSC - Human Mesenchymal Stem Cell Adipogenic Differentiation Medium (Lonza) and MSCgo). TM Specifically, the method for differentiation into adipocytes involves, for example, growing 4 × 10 mesenchymal stem cells on a gelatin-coated plate. 4 For example, cells are seeded in the osteocyte differentiation-inducing medium and cultured for 32 days. Adipocyte differentiation may be confirmed by Oil Red O staining.
[0046] The mesenchymal cells of the present invention may be in the form of spheroids, organoids, etc. Here, in this specification, "organoid" refers to a structure formed by the accumulation of cells, and typically has a structure and function similar to that of an organ in a living body. Whether a structure is an organoid can be determined, for example, by observing a sample stained as needed (e.g., alizarin red staining, hematoxylin-eosin (HE) staining, etc.) under a microscope to confirm the presence or absence of layer structure formation, or by examining the expression of marker proteins.
[0047] For example, bone organoids can be produced using the MSCs of the present invention by the method described in WO 2020 / 226043. Specifically, the MSCs of the present invention are grown in adhesion culture to form a sheet (cell sheet), the cell sheet is detached from the culture vessel, and the cell sheet is subjected to suspension culture to obtain three-dimensional mesenchymal stem cell clusters. The cell clusters are embedded in a gel and cultured in a bone differentiation-inducing medium, thereby producing bone organoids. In this method, the gel is preferably a gel primarily composed of polysaccharides, and for example, Vitrogel (The Well Bioscience) can be used.
[0048] In the differentiation induction method of the present invention, the culture conditions, culture method, cell selection method, type of basal medium, additives to the medium, specific examples and definitions of culture vessels, etc. are all incorporated by reference as described above in "1. Method for producing bone marrow niche cells."
[0049] 3. Cell Transplantation Therapy Mesenchymal stem cells obtained by the mesenchymal stem cell production method of the present invention and mesenchymal cells obtained by the mesenchymal cell production method of the present invention (hereinafter, these cells may be collectively referred to as "mesenchymal cells of the present invention") can be suitably used in cell transplantation therapy. Therefore, in another aspect of the present invention, a cell transplantation therapy agent (hereinafter, may be referred to as "cell transplantation therapy agent of the present invention") containing the mesenchymal cells of the present invention is provided. Also included within the present invention is a method for treating or preventing damage (including defects) or disease in tissue (e.g., bone tissue, cartilage tissue, adipose tissue, muscle tissue (e.g., skeletal muscle tissue, etc.)) by administering or transplanting an effective amount of the mesenchymal cells of the present invention into a mammal (e.g., human, mouse, rat, monkey, cow, horse, pig, dog, etc.) to be treated. Furthermore, "treatment of tissue damage" also includes regeneration of damaged tissue.
[0050] The purpose of transplanting the mesenchymal cells of the present invention into a living body may be to directly regenerate damaged tissue or to achieve indirect effects (e.g., paracrine effects) through factors secreted by the mesenchymal cells of the present invention. For example, mesenchymal stem cells may exert therapeutic effects in patients with acute myocardial infarction, stroke, multiple system atrophy (MSA), graft-versus-host disease, Crohn's disease, ischemic cardiomyopathy, spinal cord injury, and the like. Furthermore, as described above, the MSCs of the present invention have the ability to support hematopoietic stem / progenitor cells. Therefore, when transplanting hematopoietic stem / progenitor cells into a living body, co-transplanting the mesenchymal cells of the present invention can be expected to improve the survival rate of hematopoietic stem / progenitor cells. Therefore, the cell transplant agent of the present invention can also be used as a co-transplant agent with hematopoietic stem / progenitor cells.
[0051] When the mesenchymal cells of the present invention are used in cell transplantation therapy, it is desirable to use cells derived from iPS cells established from somatic cells with the same or substantially the same HLA genotype as the recipient individual, in order to avoid rejection. Here, "substantially the same" means that the HLA genotype is identical to that of the transplanted cells to an extent that immune responses can be suppressed with immunosuppressants, such as somatic cells with an HLA type that matches the three HLA loci (HLA-A, HLA-B, and HLA-DR) or the four HLA loci (HLA-C). If sufficient cells cannot be obtained due to age, constitution, or other reasons, they can be transplanted in a state that avoids rejection by embedding them in capsules or porous containers made of polyethylene glycol or silicone.
[0052] The mesenchymal cells of the present invention are prepared as parenteral preparations such as injections, suspensions, and infusions by mixing with a pharmaceutically acceptable carrier according to conventional means. Thus, in one embodiment, there is also provided a method for producing a cell transplantation therapy agent, which comprises the step of formulating the mesenchymal cells of the present invention. Such a production method may also comprise the step of preparing the mesenchymal cells of the present invention. Furthermore, it may also comprise the step of preserving the mesenchymal cells of the present invention.
[0053] Pharmaceutically acceptable carriers that can be included in the parenteral formulation include aqueous solutions for injection, such as physiological saline, isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.). The cell transplantation therapeutic agent of the present invention may be formulated with, for example, buffers (e.g., phosphate buffer, sodium acetate buffer), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives, antioxidants, etc. When the cell transplantation therapeutic agent of the present invention is formulated as an aqueous suspension, for example, about 1 × 10 cells are added to the aqueous solution. 6 ~Approx. 1×10 8 The cells may be suspended so that the concentration is 1000 cells / mL. The dose or transplantation amount of the mesenchymal cells or pharmaceutical composition of the present invention and the number of administrations or transplantations can be determined appropriately depending on the age, body weight, symptoms, etc. of the mammal to be administered.
[0054] The cell transplantation therapeutic agent of the present invention is provided in a cryopreserved state under conditions typically used for cryopreserving cells, and can be thawed immediately before use. In this case, it may further contain serum or a serum substitute, an organic solvent (e.g., DMSO), etc. In this case, the concentration of the serum or serum substitute is not particularly limited, but may be about 1 to about 30% (v / v), preferably about 5 to about 20% (v / v). The concentration of the organic solvent is not particularly limited, but may be about 0 to about 50% (v / v), preferably about 5 to about 20% (v / v).
[0055] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these examples in any way.
[0056] Example 1: Induction of Mesenchymal Stem Cells. iPS cells were maintained and cultured on Matrigel-coated 6-well plates until colonies reached approximately 50 cells per colony. NutriStem medium (2 mL / well) containing 10 ng / mL bFGF was used as the culture medium. The entire volume of the maintained iPS cell medium was replaced with DMEM / F12 medium containing 1% (v / v) ITS-X (100X) (Fujifilm Wako Pure Chemical Industries) and 3.5 μM CHIR99021, and differentiation induction was initiated (day 0). Culture was continued in the same medium until day 5 or 6 of culture. The medium was changed daily (at this point, infiltration of cells with fibroblast-like morphology from the cell colonies was observed). Cells were then detached from each well and passaged in gelatin-coated T75 culture flasks. The culture medium was DMEM / F12 medium (10 mL / flask) containing 1% (v / v) ITS-X (100X), 20 ng / mL bFGF, and 3.5 μM CHIR99021. The next day, the medium was replaced with medium of the same composition to remove dead cells, and the culture was continued. The medium was replaced every 2–3 days. After day 11 or 12 of culture, when the cells reached confluence, 1 / 10 of the medium containing the cells was passaged onto a gelatin-coated T75 culture flask. The culture medium was αMEM medium containing 10% FBS. 9 / 10 of the remaining medium was cryopreserved. The mesenchymal stem cells (iDP MSCs) obtained by continuing the culture until day 30 were used for the following experiments (phase-contrast microscopic images of the cells are shown in Figure 2).
[0057] For comparison, human bone marrow-derived DP MSCs (BM-DP MSCs) were established using the method described in Non-Patent Document 1. Briefly, human mononuclear cells (MNCs) were isolated from bone marrow samples of healthy donors using density gradient centrifugation, further enriched using EasySep Human Progenitor Cell Enrichment Kit (STEMCELL Technologies), and depleted of lineage-positive cells by treatment with RoboSep (STEMCELL Technologies). -BM cells were stained with 11 Lin-specific antibodies (CD2, CD16, CD24, and CD235a (DAKO), CD3, CD41, and CD66c (Beckman Coulter), CD4 and CD14 (eBioscience), CD19, and CD56 (BD Biosciences)), as well as anti-CD45 antibody (BioLegend), anti-SSEA-4 antibody (R&D Systems), and 7-aminoactinomycin D (7-AAD) (Beckman Coulter). CD271 and SSEA-4 co-positive cells were sorted using a FACSAria (BD Biosciences) or FACSAria III (BD Biosciences). The collected cells were cultured in α-MEM (Nacalai Tesque) containing 10% fetal bovine serum (BioWest) in a T-75 culture flask (BD Biosciences) at 37°C in a humidified atmosphere with 5% CO2. Antibody information is shown in Table 1.
[0058] Example 2: Surface Antigen Analysis To analyze surface marker expression in iDP MSCs, cells were stained with FITC-, PE-, APC-, or PB-conjugated anti-CD29, anti-CD31, anti-CD34, anti-CD41, anti-CD44, anti-CD45, anti-CD73, anti-CD90, anti-CD105, anti-CD271, anti-SSEA-4, anti-HLA-ABC, and anti-HLA-DR antibodies. As a negative control, samples stained with isotype IgG antibodies conjugated with FITC, PE, APC, or PB were prepared. Stained cells were analyzed using a FACSCanto II (BD Biosciences). Antibody information is shown in Table 1.
[0059]
[0060] The results are shown in Figures 2 and 3. These results demonstrated that iDP MSCs exhibited similar morphology and surface antigen expression patterns to BM-DP MSCs.
[0061] Example 3: Evaluation of the ability to support human hematopoietic stem / progenitor cells. The ability of iDP MSCs to support human hematopoietic stem / progenitor cells was evaluated by co-culturing them with human umbilical cord blood-derived hematopoietic stem cells. Human umbilical cord blood-derived hematopoietic cells were isolated by the method described in Sumide K et al., Nature Communications. 9(1):2202, 2018. Briefly, human mononuclear cells (MNCs) were isolated from healthy donor umbilical cord blood samples using density gradient centrifugation and further enriched using the EasySep Human Progenitor Cell Enrichment Kit (STEMCELL Technologies) to deplete lineage-positive cells. Then, the iDP MSCs were cultured with human umbilical cord blood-derived hematopoietic stem cells. - Cells were stained with 18 Lin-specific antibodies (CD2, CD16, CD24, and CD235a (DAKO), CD3, CD7, CD10, CD11b, CD20, and CD41 (Beckman Coulter), CD4, CD14, CD33, and CD127 (eBioscience), CD19 and CD56 (BD Biosciences), CD45RA (SouthernBiotech), and CD66b (BioLegend)). Antibodies included anti-CD45 (BioLegend), anti-CD34 (BD Biosciences), anti-CD38 (BD BioLegend), anti-CD133 / 1 (Miltenyi Biotec), anti-GPI-80 (MBL), and 7-aminoactinomycin D (7-AAD) (Beckman Coulter). Using a FACSAria (BD Biosciences) or FACSAria III (BD Biosciences), Lin was isolated from the 7-AAD-negative fraction. - CD34 + CD38 - CD133 + GPI-80 + The fractionated cells were selected. The antibody information is shown in Table 1. The cells collected by this method were classified as CD34 + This is called HCS. +HSCs were seeded at 1,000 cells per well on iDP MSCs or DP MSCs seeded as feeder cells in a 24-well plate (BD Biosciences). They were then cultured for 7 days in StemPro-34 SFM (Thermo Fisher Scientific) supplemented with 1% ITS-X (100X) (Fujifilm Wako Pure Chemical Industries, Ltd.), 10 ng / mL thrombopoietin (PeproTech), and 50 ng / mL stem cell factor (PeproTech) at 37°C in a humidified atmosphere of 5% CO2 and 5% O2. Cells were then collected by pipetting and stained with anti-CD45, anti-CD34, and 7-AAD antibodies. The CD45 activity in the 7-AAD-negative fraction was then analyzed using a FACSCanto II. + CD34 + The fraction percentages were evaluated.
[0062] The results are shown in Figure 4. Figure 4 demonstrates that iDP MSCs exhibit an expression pattern that indicates the same level of ability to support human hematopoietic stem / progenitor cells as BM-DP MSCs.
[0063] The present invention makes it possible to produce mesenchymal stem cells (niche cells) by inducing differentiation from pluripotent stem cells without using precious bone marrow samples, which require invasive collection. The mesenchymal stem cells have the ability to support hematopoietic stem / progenitor cells and can also be used as starting cells for inducing differentiation into mesenchymal cells, making them extremely useful, particularly in the medical field.
[0064] This application is based on patent application No. 2023-086944 filed in Japan (filing date: May 26, 2023), the contents of which are incorporated in their entirety herein.
Claims
1. A method for producing mesenchymal stem cells from pluripotent stem cells, comprising: (1) culturing the pluripotent stem cells in a medium containing a GSK3β inhibitor to obtain fibroblast-like cells; and (2) culturing the fibroblast-like cells obtained in step (1) in a medium containing a fibroblast growth factor and a GSK3β inhibitor to obtain mesenchymal stem cells.
2. The method according to claim 1, further comprising the step of: (3) expanding the cells obtained in step (2).
3. The method according to claim 1 or 2, wherein at least one of the fibroblast growth factors in step (2) is bFGF.
4. The method according to any one of claims 1 to 3, wherein the mesenchymal stem cells are positive for CD271 and SSEA-4.
5. The method according to any one of claims 1 to 4, wherein the pluripotent stem cells are induced pluripotent stem cells.
6. Mesenchymal stem cells obtained by the method according to any one of claims 1 to 5.
7. A method for maintaining hematopoietic stem / progenitor cells, comprising a step of co-culturing hematopoietic stem / progenitor cells with the cells according to claim 6.
8. A method for producing mesenchymal cells, comprising the step of inducing differentiation of the cells according to claim 6.
9. A cell transplantation therapy comprising the cells according to claim 6 or the cells obtained by the method according to claim 8.
10. The agent according to claim 9, comprising hematopoietic stem / progenitor cells.
Citation Information
Patent Citations
Preparation method and application of trunk neural crest-derived mesenchymal stem cells
CN115011553A
Novel method and culture medium for culturing pluripotent stem cells
JP2017195892A
Stepwise method for producing various cells from pluripotent stem cells
WO2019177118A1
Method for producing nephron progenitor cells
WO2020213734A1
